Harvest Group Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 648 shares of the medical research company’s stock, valued at approximately $177,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund lifted its holdings in shares of Thermo Fisher Scientific by 44,296.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after purchasing an additional 19,521,889 shares during the period. Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $946,280,000. FMR LLC increased its position in Thermo Fisher Scientific by 33.4% during the 4th quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after purchasing an additional 2,172,574 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock valued at $5,858,214,000 after purchasing an additional 944,035 shares in the last quarter. Finally, Cantillon Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 91.3% in the 4th quarter. Cantillon Capital Management LLC now owns 1,024,930 shares of the medical research company’s stock valued at $229,369,000 after purchasing an additional 489,081 shares in the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.
Shares of Thermo Fisher Scientific stock traded down $0.98 during trading on Friday, hitting $285.26. The stock had a trading volume of 1,381,012 shares, compared to its average volume of 1,633,012. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61. The firm has a market cap of $114.08 billion, a price-to-earnings ratio of 25.65, a price-to-earnings-growth ratio of 1.87 and a beta of 1.08. Thermo Fisher Scientific Inc. has a fifty-two week low of $202.83 and a fifty-two week high of $288.07.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Investors of record on Friday, June 14th will be paid a dividend of $0.19 per share. The ex-dividend date is Thursday, June 13th. This represents a $0.76 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 6.83%.
TMO has been the topic of several research analyst reports. Barclays lifted their price objective on Thermo Fisher Scientific from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Deutsche Bank boosted their price target on Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. UBS Group boosted their price target on Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. BTIG Research lifted their price objective on Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. Finally, Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $270.00 to $288.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $295.92.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the transaction, the chief financial officer now directly owns 40,029 shares in the company, valued at approximately $10,739,380.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director C Martin Harris sold 275 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the transaction, the director now owns 6,433 shares in the company, valued at $1,741,606.09. The disclosure for this sale can be found here. Insiders sold a total of 53,488 shares of company stock valued at $14,600,474 in the last quarter. Corporate insiders own 0.45% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was reported by Rockland Register and is the property of of Rockland Register. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://rocklandregister.com/2019/06/14/harvest-group-wealth-management-llc-buys-new-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.